Amgen: New economic analysis of cholesterol-lowering drug Repatha - Science Business

Amgen: New economic analysis of cholesterol-lowering drug RepathaScience Business... therapy is both clinically beneficial and cost-effective,” said Gregg Fonarow, professor of medicine, UCLA David Geffen School of Medicine, who is lead author of the study, published in the Journal of the American Medical Association (JAMA) Cardiology.